Kaspar L, Karnik R, Sehnal E, Zajicek P, Ziegler B, Slany J
Medical Department, Krankenanstalt Rudolfstiftung, Vienna.
Drugs. 1987;33 Suppl 3:179-82. doi: 10.2165/00003495-198700333-00030.
As part of a randomised multicentre study, 16 patients with acute myocardial infarction were treated with either anisoylated plasminogen streptokinase activator complex (APSAC) administered as an intravenous bolus of 30U or 250,000U of streptokinase by the intracoronary route. The reperfusion was documented angiographically during a 90-minute period and possible reocclusion was assessed at 90 minutes and 24 hours after the start of therapy. The percentage of reperfusion obtained in the APSAC group was 83% versus 63% in the streptokinase group. One reocclusion was seen after 24 hours in the APSAC group. Fibrinolytic activity was more pronounced in the APSAC group but there were no major bleeding problems in either group. The administration of 30U of APSAC by an intravenous bolus injection produced results at least as good as those obtained with intracoronary streptokinase and in addition offered the advantage of a simpler and quicker administration.
作为一项随机多中心研究的一部分，16例急性心肌梗死患者接受了以下两种治疗之一：静脉推注30U茴香酰化纤溶酶原链激酶激活剂复合物（APSAC），或通过冠状动脉内途径给予250,000U链激酶。在90分钟内通过血管造影记录再灌注情况，并在治疗开始后90分钟和24小时评估可能的再闭塞情况。APSAC组的再灌注百分比为83%，而链激酶组为63%。APSAC组在24小时后出现1例再闭塞。APSAC组的纤溶活性更明显，但两组均未出现严重出血问题。静脉推注30U APSAC产生的效果至少与冠状动脉内链激酶相当，此外还具有给药更简单、更快的优点。
